The origins and future of patriarchy: the biological background of gender politics

Malcolm Potts, Martha Campbell

Introduction

Langur monkeys live in social groups consisting of several females and their offspring together with one alpha male, who fights off other males and controls the females. When primatologist Sarah Hrdy studied these monkeys in the 1970s, she found that after an alpha male was defeated then the new dominant male set about systematically to kill the suckling infants sired by the previous male. Like everything in evolution this is not a conscious strategy, but those males who had a mutation coding such behaviour would have left more genes in the next generation, because killing the baby cut short the interval of lactational amenorrhoea making the female immediately available for impregnation by the new male.

Female langur monkeys try to defend their infants from the murderous males but eventually the stronger male wins. Commenting on the differing reproductive agenda Hrdy has written: “In only a few cases will the self interest of consorts overlap”. A parallel behaviour has also evolved in lions and gorillas – and it seems in Homo sapiens. Daly and Wilson, using criminological data from North America, have shown that the relative risk of a non-biological father killing the child of the women he has sex with is 60 times greater than that of a biological father. This effect lasts for precisely the time we would expect a woman to breastfeed in a hunter–gathering society. As every epidemiologist knows, a 60-fold risk is a compelling statistic.

Darwin was the first person to understand that men and women can have different reproductive agendas for explicable biological reasons. He saw that what he called the “war of nature” exists not only between species, but also between the two sexes of the same species. Commenting on sexual dimorphism, where the male is bigger than the female, Darwin wrote: “the male … seems to owe his greater size to his ancestors having fought with other males during many generations”.3 Sexually dimorphic species are either polygamous or promiscuous in their mating patterns, while among genuinely monogamous species (e.g. penguins) the two sexes are the same size, or the male is smaller. The fact that men, on average, are 5–12% larger than women4 and have greater upper body strength betrays the fact that we are descended from a promiscuous or polygynous hominid stock. Although behaviour itself does not fossilise, a lot can be inferred from dry bones and studies of australopithecine fossils, which suggest the males matured more slowly and grew to be larger than females.5

Those working in reproductive health are vividly aware of how much more time and energy a woman puts into pregnancy and lactation than a man puts into depositing sperm. Evolution predicts that the sex making most biological investment in the next generation will be cautious in their mating choices, while the one that makes the least investment is likely to be more competitive, less discriminating and more risk-taking. It is a generalisation borne out by the behaviour of all other species, including our own. Evolutionary psychology posits that certain behaviours are universal because they helped the genes of a particular species to survive across the generations. In the case of human beings, such behavioural predispositions evolved to adapt us to the Stone Age rather the modern world. Patriarchy, we suggest, has deep roots in human evolution.6

The rise of patriarchy

Hunter–gatherer societies

For over 95% of the time since Homo sapiens became a distinct species, we lived in small hunter–gatherer clans, and some survive today. Among such societies, the menarche often occurs in the late teens, and pregnancies are naturally spaced by long intervals of breastfeeding. The total fertility rate is between 3.5 and 7.8.7 As among other sexually dimorphic primates, some men in hunter–gatherer societies use their greater strength to dominate women. Among the Yanomamo of Venezuela and Brazil, some men beat their wives with sticks, cut them with machetes, hold hot timbers against them, or even fire a barbed arrow into the buttocks.8 Among the less violent ‘Kung of the Kalahari some men still try to dominate women. A woman’s brothers may sometimes come to the rescue of a woman ill treated by her husband. In a society without property, a woman may walk away from violence although she will have to continue to support any children.9

Some preliterate societies are slightly less paternalistic than others. While the myth of some sort of ancestral matriarchal society has attracted some writers, it has no foundation in anthropology or history. For example, in some hunter–gatherer societies the girl’s family decides whom she will marry, or in more war-like tribes women are captured, raped and then assigned to a particular man. Sometimes men and women choose their sexual partners, as among the Ayoreo in Paraguay, where young men and women make romantic attachments. Anthropologists Bugos and McCarthy describe Ayoreo women as a “charming friend, devoted wife and doting mother”. However, up to one-third of firstborn children are killed at birth by their mothers.10 In this case women are optimising their reproductive potential over the long term, because if a romantic relationship fails, a woman will not receive the support she needs from the father of the child, while over the next few years of breastfeeding and childcare she will be excluded from exploring a new romantic relationship. The most cost-effective reproductive strategy is to kill the child and start again. The older the woman, the less effective this strategy, and female infanticide falls with the mother’s age. In the West, women make similar decisions over optimising their lifelong reproductive potential, but they do so through contraception and abortion.

Despotic societies

Across history and across cultures, rich and powerful men have had more sex than those lower in the social hierarchy. Large harems were the order of the day for King Solomon, the Pharaohs of Egypt, the Aztec Kings, the Mongol rulers,
the Turkish Sultans and the Chinese Emperors. The 19th century kings of Dahomey had harems of literally thousands of women. Some of the many women belonging to the king were drafted as a bodyguard, the so-called ‘Amazons’. Some 8% of men in Central Asia and one in 200 men world wide have an identical Y chromosome and the most plausible explanation of this curious fact is that these men are all descendants of Genghis Khan (d. 1227). He had a large harem and delighted in raping women captured in warfare, and his children behaved the same way through out the following century. In Ireland, a study of the Y chromosome of almost 800 men found many shared a common genetic signature thought to show descent from a Dark Age despot called Niall. Uí Neill is an Irish surname meaning “descendent of Niall”, and studies show that men with this name are likely to have an identical Y chromosome. Keeping a harem not only enables a despot to father many children, but it also deprives other men of wives. In pre-conquest Peru, the great Inca at the top of the social pyramid had the pick of the empire and the men at the bottom often went unmarried. In Dahomey, the king was forced to subsidise prostitution for those who could not find a wife, bringing the price of sex down to one-tenth the cost of a dead chicken. Despots imposed patriarchial laws with ferocious consistency. Rich men cloistered their women behind high walls, or bound their feet so they could neither work in the field nor run away. If a man had intercourse with one of the 700 wives of the Great Inca, then the guilty man was executed along with his wife, relatives, servants, all the people in his village and his farm animals, “without leaving a sucking nor a crying baby”. The occasional Roman emperor, such as Trajan, was less despotice than others and did not keep a large harem, but Emperor Commodus is said to have had 300 concubines and every male slave owner had automatic sexual rights over any slave he found attractive. It was in this world that the Christian teaching about sex arose. St Augustine (d. 430 AD) saw God as an arbitrary judge who would punish women, like the Ayoreo, in order to optimise lifelong reproduction, resorted to killing their infants, only they did it indirectly by placing their unintended children in foundling hospitals. Without breastfeeding, or even clean water, 10 204 of the 14 934 babies admitted to the London Foundling Hospital in the 1770s died.

The shadow of patriarchy

By 1919 the birth rate in Belgium had fallen slightly compared with 1880–1910 in those arrondissements that voted for Catholic political parties but by up to 80% in those which had turned their back on religious patriarchy. Throughout the rest of the 20th century and into the 21st, patriarchy has continued to cast a sinister shadow. In North America, the National Institutes of Health (NIH) was forbidden to sponsor contraceptive research until 1968. Even today, the NIH is not permitted to fund research on possible abortifacient drugs. In Ireland, the National Family Planning Association was fined £500 in 1990 for selling a condom in the Virgin Music Megastore in Dublin. To try to stop contraceptives and erectile dysfunction (ED) is particularly revealing. The physiological basis of hormonal contraception was described in 1921, but it took three decades before Margaret Sanger could persuade scientists to develop the first OC. And when they did, contraception was still illegal in Massachusetts and no large pharmaceutical company wanted to touch the new product. There were no laws against studying male erections, and when Viagra® was discovered it was developed immediately as a blockbuster drug. In 1962, the Second Vatican Council replaced a theology of marriage based exclusively on the procreation of children by one built on mutual love, and the teaching on contraception was expected to change, at least in relation to the newly invented OCs. The Harvard obstetrician, John Rock, who led the clinical work on the first OCs, was a
devout Roman Catholic who attended Mass every morning. In 1963 he wrote *The Time Has Come*, arguing the Pill was morally acceptable, but in July 1968 Pope Paul IV issued the encyclical *Humanae Vitae*, to: “exclude … any action … specifically intended to prevent procreation – whether as an end or a means”. John Rock and millions of others stopped going to Mass. The Pope was reaffirming Saint Augustine’s denial of the dual biological purposes of human intercourse.²¹²²

Referring to nocturnal erections, Augustine wrote: “these members are rightly called pudenda [parts of shame] because they excite themselves just as they like, in opposition to the mind of their master as if they were their own masters”. Yet no theologian or prelate has condemned Viagra or Levitra²³ for encouraging the “parts of shame to excite themselves”. Every death with the original high-dose OCs hit the headlines, and the United States Congress considered taking the Pill off the market. Over 500 deaths²² have been reported with ED therapies, including perhaps one head of state – President Abacha of Nigeria. As in the case of OCs, ED deaths are not necessarily causally related, but nevertheless it is perhaps revealing that there has been no call to take these drugs off the market. In fact, many North American medical insurance companies have been quicker to pay for ED therapies than OCs.

Evolutionary psychology looks for behaviours which are universal and the shadow of yesterday’s patriarchal traditions are not limited to the West. Efforts to register OCs in Japan began in 1965. Initially, use was refused because Japanese women were said to be physiologically different from Western women; then it was said OC use would spread HIV; finally in 1998 registration was refused for a reason paralleling the obscurantism of medieval theologians – it was claimed that artificial hormones in sewage would feminise fish. The following year, Viagra was approved in a record short time of 6 months. Eventually, the asymmetry between the two drugs had become so grotesque that the Pill was finally approved on Viagra’s coat tails, 35 years after the initial application.

The end of patriarchy?
The fight for reproductive rights and freedom can be seen as a long, painful struggle between the evolved male reproductive agenda, which is predisposed to control female patterns of mating and childbirth, and the female reproductive agenda, which benefits from the widest possible choice of mate and freedom to optimise lifelong patterns of childbearing. No woman can be free unless she can control if and when to have children. Male attempts to control female reproductive choices have a long history. It was women who discovered and marketed most traditional contraceptives and abortifacients, and men who wrote laws and preached theological arguments to restrict or condemn their use.

Evolution is the outcome of random mutations, tested in the real world of natural competition. Evolution is about what works; not what is fair, moral or just. The insights that can be drawn from evolutionary psychology are not excuses for cruelty, but insights that can help us confront cruelty and injustice. This is particularly important when we are trying both to understand the origins of human patriarchy and striving to eliminate patriarchy in the future. Patriarchy has deep roots in human behaviour, a terrible record of pain and suffering in historic societies, and even today patriarchal forces in many developing countries continue to enslave half the human race and remain near the surface in the West. When young American men were asked to imagine what they would do if they could rape a woman and be certain they would never be found out, one-third said they might rape.²³

While 185 countries have ratified the 1979 Convention on the Elimination of All Forms of Discrimination Against Women, hundreds of millions of women still suffer from violence, sexual abuse and unequal access to the law. Gonoroshasthaya Kendra (“People’s Health Centre”) is a non-governmental organisation in Bangladesh that has brought about substantial improvements in maternal and infant mortality and worked hard to improve the status of women. Yet when a careful review was conducted of 506 consecutive deaths in women aged 15 to 49 years, 14% of women’s deaths were related to pregnancy and childbirth, and a remarkable 5.5% committed suicide as a result of domestic violence and abuse by in-laws.²⁴ Even today, a pregnant woman in the USA is more likely to be murdered, nearly always by a sexual partner, than to die of any single disease during pregnancy, such as heart or kidney failure. To return to Saint Augustine, he explicitly praised his own mother, Monica, for never complaining about his father’s infidelities, maintaining that the correct way to escape domestic violence was for a wife never to criticise her husband, however badly he treated her.

From the Stone Age to the second Bush administration, the male predisposition to dominate the reproductive lives of women often holds sway. Britain is discussing whether pharmacists should distribute OCs more than three decades after the evidence base for non-physician prescription was established. In the USA, the Bush administration has overridden expert advice on emergency contraception and censored statements on condoms. It is useful, we suggest, to see such arguments as less about morals and more about patriarchy. Looked at this way, then Britain and the other developed nations should be as eager to bring contraception and safe abortion to women in the developing world in the 21st century as they were to end slavery in the 19th century.

**Statements on funding and competing interests**

**Funding** None identified.

**Competing interests** None identified.

References

Effects of continuous versus cyclical oral contraception: a randomized controlled trial.

There is continuing interest in the use of long- cycle and combined hormonal contraceptive regimens to improve premenstrual and menstrual ill-health. This paper is a well-designed, randomised, double-blind trial involving a total of 62 healthy women taking either combined pills for 21 days plus 7 days of placebo over six cycles or continuous therapy for 168 days. It was surprising to see that a 20 µg ethinylestradiol and 1 mg norethindrone acetate pill was chosen for this study. The authors explained that previously published work had reported more days of amenorrhoea and fewer days of spotting with such a preparation.

The subjects were studied for three menstrual cycles prior to enrolment. No hormonal contraception was taken during this time. They were then seen regularly during the ‘active’ phase of the study. Women under 20% of women dropped out once taking the study medication with approximately half giving ‘uncomfortable with the side effects’ as the reason. The overall results are similar to previous published work with the total number of bleeding days similar between the two groups and significantly less moderate/heavy bleeding days occurring with the continuous therapy (mean 5.2 ± 6.8 days) than cyclic dosing (mean 11 ± 8.5 days; p = 0.005). Both groups had less bleeding overall; however unpredictable breakthrough bleeding was more common in the continuous regimen cohort (37.6 ± 38.8 vs 18.3 ± 17.2 days). These healthy, normal women taking continuous active pills had less associated menstrual pain and a favourable improvement in ‘behaviour’ during the premenstrual phase only. Perhaps a greater improvement would be expected if the therapy was to be repeated in women with premenstrual syndrome or dysmenorrhoea.

Women taking the continuous regimen had greater ovarian and endometrial suppression with one woman ovulating once. In the cyclic group rebound ovulation or suspected ovulation occurred in 11/60 cycles (18%). These results suggest that long-cycle therapy should be more efficacious, however this needs to be borne out in practice.

Reviewed by Diana Mansour, FRCCG, FSRH Consultant in Community Gynaecology, Contraception and Sexual Health Service, Newcastle upon Tyne Primary Care Trust, Newcastle upon Tyne, UK.


Implanon® (etonogestrel implant) is currently the only contraceptive implant licensed in the UK and is familiar to most general practitioners and sexual and reproductive health care workers. This report, funded by Organon, provides an overview of the implant’s efficacy, safety and bleeding patterns. It is a summary of the findings of 11 clinical trials undertaken in contraceptive clinics in the USA, Chile, Asia and Europe.

In the 941 patients enrolled, no pregnancies occurred with the implant in situ, but there were six reported pregnancies within 14 days of implant removal. This gave a cumulative Pearl index of 0.38.

Of the adverse events reported, those that were most likely to be attributed to the implant included headache (15.5%), weight gain (12.0%), acne (11.8%), breast pain (10.2%), emotional lability (5.8%) and abdominal pain (5.2%). Complications from implant insertion and removal were infrequent.

Due to the testosterogen content of the implant, bleeding irregularities were expected and occurred with no particular pattern. Comparisons between the bleeding patterns of patients using Norplant® and Implanon were made, and showed Implanon to cause few bleedings and spotting days and more amenorrhoea. However, the statistical significance of these findings is limited by the small number of subjects involved in this part of the analysis.

Interestingly, geographical differences were noted when considering reasons for discontinuation. In the North American and European populations, bleeding irregularities were considered much less acceptable, contributing to 14% of premature removals of the implant, compared to only 4% in Southeast Asia, Chile and Russia. Side effects that were reported as reasons for discontinuation more frequently also showed regional differences with symptoms such as emotional lability, depression and weight gain more commonly cited by North American patients.

This report highlights the contraceptive effectiveness of Implanon and its general tolerability; however, the geographical variation in results must be considered when counselling patients in the UK about common side effects and bleeding patterns in an attempt to minimise patient dissatisfaction. In addition, patients with a high body mass index were excluded from the studies, therefore these trials do not predict efficacy of Implanon in obese women.

Reviewed by Kate L Darlow, MBChB, DFSRH, Specialist Registrar, St John’s Hospital, Livingston, West Lothian, UK.


A hormonal contraceptive for men has been the subject of active research for over 50 years. During this time a large number of studies have been carried out that have clearly demonstrated a number of important points including, most crucially, that hormone-induced spermatogenic suppression can provide effective contraception for men, and that this is fully reversible. This can be achieved either with high doses of testosterone alone or, to reduce the dose, the testosterone is more usually given in combination with a progestogen, which is the case in this study.

Studies in this field have often been limited by small sample size and difficulties in comparing different treatments. It is therefore very encouraging to learn of this double-blind placebo-controlled design involving 354 men who received either a low- or high-release etonogestrel implant (the low-release implant being similar to Implanon®) combined with one of three testosterone regimens using the long-acting injectable formulation testosterone undecanoate or placebo. Overall, this was a test of very effective regimens, and the placebo group was useful in highlighting the specific side effects. However, as in many previous studies there remain a small number of men who seem resistant to hormonal suppression, and therefore should this type of approach become widespread in use then a test of efficacy, as for example after a vasectomy, would need to be incorporated. Differences between groups were slight.

Disappointingly, however, both Organon and Schering have announced that they do not intend to pursue this line of research. Optimism is only maintained by the ongoing efforts of bodies such as the World Health Organization and the National Institutes of Health who continue to be active in this field.

Reviewed by Richard A Anderson, PhD, MBCCG Professor of Clinical Reproductive Science, Centre for Reproductive Biology, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK.